Objetivo
The oncogenic fusion protein BCR/ABL causes human leukemia. A specific inhibitor of BCR/ABL is an effective treatment of tumors in vivo. The project aims at investigating molecular mechanisms underlying resistance to the inhibitor in vivo.
Ámbito científico
Convocatoria de propuestas
Data not availableRégimen de financiación
RGI - Research grants (individual fellowships)Coordinador
20133 MILANO
Italia